Ironwood Pharmaceuticals Inc (IRWD) — SEC Filings
Ironwood Pharmaceuticals Inc (IRWD) — 45 SEC filings. Latest: 8-K (May 7, 2026). Includes 25 8-K, 9 SC 13G/A, 6 10-Q.
View Ironwood Pharmaceuticals Inc on SEC EDGAR
Overview
Ironwood Pharmaceuticals Inc (IRWD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: On December 18, 2025, Ironwood Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also indicates other events and includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Boston, MA.
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 3 bearish, 40 neutral, 2 mixed. The dominant filing sentiment for Ironwood Pharmaceuticals Inc is neutral.
Filing Type Overview
Ironwood Pharmaceuticals Inc (IRWD) has filed 25 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 SC 13G, 9 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of IRWD's 33 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $248.44M |
| Net Income | $40.08M |
| Cash Position | $140.41M |
| Operating Margin | 37.0% |
| Total Assets | $396.06M |
| Total Debt | $584.51M |
Key Executives
- Dr. Lisa A. DeTora
- Mr. David M. R. Johnson
- Ms. Sarah K. Kelly
- Mr. Michael J. Heffernan
- Dr. Lisa M. DeTora
- Mr. David M. Stack
- Dr. Christopher M. Varma
- Michael L. Smith
- Mark Currie, Ph.D.
- Alexander Denner, Ph.D.
- Andrew Dreyfus
- Jon Duane
- Marla Kessler
- Thomas McCourt
- Julie McHugh
Industry Context
The pharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on collaborative arrangements and strategic partnerships to share risks and costs, and to access new markets or technologies. The competitive landscape demands continuous innovation and efficient commercialization of new therapies.
Top Tags
financial-reporting (6) · 8-k (4) · 10-Q (4) · pharmaceuticals (4) · institutional-ownership (4) · Pharmaceuticals (3) · corporate-governance (3) · financials (3) · amendment (3) · passive-investing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $40.08M | Increased from $3.65 million in Q3 2024, representing over 1000% growth. |
| Collaborative arrangements revenue for Q3 2025 | $122.06M | Increased from $91.59 million in Q3 2024. |
| Total revenues for nine months ended Sep 30, 2025 | $248.44M | Decreased from $260.87 million in the same period of 2024. |
| Research and development expenses for Q3 2025 | $22.47M | Decreased from $29.83 million in Q3 2024. |
| Selling, general and administrative expenses for Q3 2025 | $21.91M | Decreased from $36.11 million in Q3 2024. |
| Current portion of convertible senior notes | $199.51M | Increased from zero at December 31, 2024, indicating near-term maturity. |
| Cash and cash equivalents as of Sep 30, 2025 | $140.41M | Increased from $88.56 million at December 31, 2024. |
| Restructuring, net for nine months ended Sep 30, 2025 | $20.51M | Increased from $2.52 million in the same period of 2024, reflecting strategic adjustments. |
| Revolving credit facility | $385.00M | Fully utilized as of September 30, 2025 and December 31, 2024. |
| Acquisition Value | $1.0B | Total value of the definitive agreement for Ironwood Pharmaceuticals. |
| Expected Closing | Q4 2025 | Anticipated timeframe for the completion of the acquisition. |
| Total Revenues | $110.0M | Decreased from $112.0M in Q2 2024, indicating stagnant top-line growth. |
| Net Income | $25.0M | Fell from $35.0M in Q2 2024, signaling reduced profitability. |
| LINZESS Collaboration Revenue | $105.0M | Primary revenue source for Q2 2025, highlighting product concentration risk. |
| R&D Expenses | $30.0M | Increased from $28.0M in Q2 2024, showing continued investment in pipeline. |
Forward-Looking Statements
- {"claim":"LSV Asset Management will continue to hold a significant, passive stake in Ironwood Pharmaceuticals through 2024.","entity":"LSV Asset Management","targetDate":"December 31, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ironwood Pharmaceuticals Inc (IRWD)?
Ironwood Pharmaceuticals Inc has 45 recent SEC filings from Jan 2024 to May 2026, including 25 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IRWD filings?
Across 45 filings, the sentiment breakdown is: 3 bearish, 40 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Ironwood Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ironwood Pharmaceuticals Inc (IRWD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ironwood Pharmaceuticals Inc?
Key financial highlights from Ironwood Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IRWD?
The investment thesis for IRWD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ironwood Pharmaceuticals Inc?
Key executives identified across Ironwood Pharmaceuticals Inc's filings include Dr. Lisa A. DeTora, Mr. David M. R. Johnson, Ms. Sarah K. Kelly, Mr. Michael J. Heffernan, Dr. Lisa M. DeTora and 10 others.
What are the main risk factors for Ironwood Pharmaceuticals Inc stock?
Of IRWD's 33 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Ironwood Pharmaceuticals Inc?
Recent forward-looking statements from Ironwood Pharmaceuticals Inc include guidance on {"claim":"LSV Asset Management will continue to hold a significant, passive stake in Ironwood Pharmaceuticals through 20.